| 发明名称 | Method for treating triple-negative breast cancer using AMPI-109 | ||
| 摘要 | A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer. | ||
| 申请公布号 | US9539231(B2) | 申请公布日期 | 2017.01.10 |
| 申请号 | US201414158238 | 申请日期 | 2014.01.17 |
| 申请人 | The Regents of the University of Colorado, a body corporate;Trustees of Boston University | 发明人 | Gari Hamid;Lambert Jim;Lucia Scott;Ray Rahul;Thor Ann |
| 分类号 | A61K31/215;A61K31/337;A61K31/704 | 主分类号 | A61K31/215 |
| 代理机构 | Hamilton DeSanctis & Cha, LLP | 代理人 | Cha Don D.;Hamilton DeSanctis & Cha, LLP |
| 主权项 | 1. A method for treating triple-negative breast cancer, comprising: administering a drug comprising AMPI-109 in an amount effective for treating or preventing triple-negative breast cancer to a patient in need thereof, wherein AMPI-109 has a chemical structure of | ||
| 地址 | Denver CO US | ||